Charles River Now Offers MucilAir™ Human Airway Toxicity Test
April 24, 2012 - MucilAir™ was evaluated for use in predicting upper airway toxicity by treating tissues with increasing concentrations of sodium dodecyl sulfate (SDS). Evaluations were performed to assess monolayer integrity (transepithelial electrical resistance [TEER]), membrane integrity (lactate dehydrogenase [LDH] release), metabolic competence (resazurin metabolism) and inflammatory mediator (IL-8) release. Histology and scanning electron microscopy (SEM) were used to assess morphology.
Scanning electron micrograph of MucilAir® (x6400)
When treated with SDS, it was concluded that MucilAir™ displayed dose-dependent responses, with cytotoxicity visualized by histology at ≥0.6 mM and measured chemically at ≥1.25 mM. Monolayer integrity (TEER) and marker release (LDH and IL-8) patterns were comparable between equivalently dosed units. These data support the use of MucilAir™ as a relevant model for airway toxicity studies.
For more information, please contact us at 1.877.CRIVER.1 or email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 21–May 24
RDD Europe 2013 is a forum for pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.